Literature DB >> 26373946

Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions.

Eberhard Nieschlag1,2, Elena Vorona3.   

Abstract

Since the 1970s anabolic androgenic steroids (AAS) have been abused at ever increasing rates in competitive athletics, in recreational sports and in bodybuilding. Exceedingly high doses are often consumed over long periods, in particular by bodybuilders, causing acute or chronic adverse side effects frequently complicated by additional polypharmacy. This review summarizes side effects on non-reproductive organs and functions; effects on male and female reproduction have been recently reviewed in a parallel paper. Among the most striking AAS side effects are increases in haematocrit and coagulation causing thromboembolism, intracardiac thrombosis and stroke as well as other cardiac disturbances including arrhythmias, cardiomyopathies and possibly sudden death. 17α-alkylated AAS are liver toxic leading to cholestasis, peliosis, adenomas and carcinomas. Hyperbilirubinaemia can cause cholemic nephrosis and kidney failure. AAS abuse may induce exaggerated self-confidence, reckless behavior, aggressiveness and psychotic symptoms. AAS withdrawal may be accompanied by depression and suicidal intentions. Since AAS abuse is not or only reluctantly admitted physicians should be aware of the multitude of serious side effects when confronted with unclear symptoms.

Entities:  

Keywords:  Adverse effects; Aggression; Anabolic androgenic steroids (AAS); Cardiomyopathies; Depression; Hepatotoxicity; Performance and appearance enhancing drugs (PAED); Stroke

Mesh:

Substances:

Year:  2015        PMID: 26373946     DOI: 10.1007/s11154-015-9320-5

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  107 in total

1.  Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study.

Authors:  V Di Bello; D Giorgi; M Bianchi; A Bertini; M T Caputo; G Valenti; O Furioso; L Alessandri; M Paterni; C Giusti
Journal:  Med Sci Sports Exerc       Date:  1999-04       Impact factor: 5.411

Review 2.  Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis.

Authors:  Giovanni Corona; Elisa Maseroli; Giulia Rastrelli; Andrea M Isidori; Alessandra Sforza; Edoardo Mannucci; Mario Maggi
Journal:  Expert Opin Drug Saf       Date:  2014-08-19       Impact factor: 4.250

3.  The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20-29-year-old Danish men: Odense Androgen Study.

Authors:  Torben Leo Nielsen; Claus Hagen; Kristian Wraae; Lise Bathum; Rasmus Larsen; Kim Brixen; Marianne Andersen
Journal:  Eur J Endocrinol       Date:  2010-02-04       Impact factor: 6.664

4.  Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?

Authors:  A Urhausen; T Albers; W Kindermann
Journal:  Heart       Date:  2004-05       Impact factor: 5.994

5.  Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone.

Authors:  T A M Karila; J E Karjalainen; M J Mäntysaari; M T Viitasalo; T A Seppälä
Journal:  Int J Sports Med       Date:  2003-07       Impact factor: 3.118

6.  Left ventricular wall thickening does occur in elite power athletes with or without anabolic steroid Use.

Authors:  R D Dickerman; F Schaller; W J McConathy
Journal:  Cardiology       Date:  1998-10       Impact factor: 1.869

7.  Testosterone action on erythropoiesis does not require its aromatization to estrogen: Insights from the testosterone and estrogen treatment of two aromatase-deficient men.

Authors:  Vincenzo Rochira; Lucia Zirilli; Bruno Madeo; Laura Maffei; Cesare Carani
Journal:  J Steroid Biochem Mol Biol       Date:  2008-12-30       Impact factor: 4.292

8.  Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases.

Authors:  Neeral L Shah; Isabel Zacharias; Urmila Khettry; Nezam Afdhal; Fredric D Gordon
Journal:  Clin Gastroenterol Hepatol       Date:  2008-01-09       Impact factor: 11.382

9.  Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report.

Authors:  Philipp Solbach; Andrej Potthoff; Hans-Jürgen Raatschen; Bisharah Soudah; Ulrich Lehmann; Andrea Schneider; Michael J Gebel; Michael P Manns; Arndt Vogel
Journal:  BMC Gastroenterol       Date:  2015-05-20       Impact factor: 3.067

Review 10.  Anabolic steroids, acute myocardial infarction and polycythemia: a case report and review of the literature.

Authors:  Kathleen Stergiopoulos; Joseph J Brennan; Robin Mathews; John F Setaro; Smadar Kort
Journal:  Vasc Health Risk Manag       Date:  2008
View more
  25 in total

Review 1.  Do anabolic-androgenic steroids have performance-enhancing effects in female athletes?

Authors:  Grace Huang; Shehzad Basaria
Journal:  Mol Cell Endocrinol       Date:  2017-07-12       Impact factor: 4.102

Review 2.  Drug-induced Liver Injury: The Hepatic Pathologist's Approach.

Authors:  David E Kleiner
Journal:  Gastroenterol Clin North Am       Date:  2017-06       Impact factor: 3.806

3.  Long-term anabolic steroids in male bodybuilders induce cardiovascular structural and autonomic abnormalities.

Authors:  Octávio Barbosa Neto; Gustavo Ribeiro da Mota; Carla Cristina De Sordi; Elisabete Aparecida M R Resende; Luiz Antônio P R Resende; Marco Antônio Vieira da Silva; Moacir Marocolo; Rafael Silva Côrtes; Lucas Felipe de Oliveira; Valdo José Dias da Silva
Journal:  Clin Auton Res       Date:  2017-10-10       Impact factor: 4.435

Review 4.  Molecularly imprinted polymers for the detection of illegal drugs and additives: a review.

Authors:  Deli Xiao; Yue Jiang; Yanping Bi
Journal:  Mikrochim Acta       Date:  2018-04-04       Impact factor: 5.833

Review 5.  Anabolic androgenic steroid abuse in the United Kingdom: An update.

Authors:  Carrie Mullen; Benjamin J Whalley; Fabrizio Schifano; Julien S Baker
Journal:  Br J Pharmacol       Date:  2020-03-03       Impact factor: 8.739

6.  Immunodeficiency as a side effect of anabolic androgenic steroid abuse: a case of necrotizing myofasciitis.

Authors:  Giuseppe Bertozzi; Francesco Sessa; Francesca Maglietta; Luigi Cipolloni; Monica Salerno; Carmela Fiore; Palmira Fortarezza; Pietrantonio Ricci; Emanuela Turillazzi; Cristoforo Pomara
Journal:  Forensic Sci Med Pathol       Date:  2019-07-29       Impact factor: 2.007

Review 7.  The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.

Authors:  L Di Luigi; F Pigozzi; P Sgrò; L Frati; A Di Gianfrancesco; M Cappa
Journal:  J Endocrinol Invest       Date:  2019-11-16       Impact factor: 4.256

Review 8.  Effects of Anabolic Androgenic Steroids on the Reproductive System of Athletes and Recreational Users: A Systematic Review and Meta-Analysis.

Authors:  Maria A Christou; Panagiota A Christou; Georgios Markozannes; Agathocles Tsatsoulis; George Mastorakos; Stelios Tigas
Journal:  Sports Med       Date:  2017-09       Impact factor: 11.136

9.  Subchronic nandrolone administration reduces cardiac oxidative markers during restraint stress by modulating protein expression patterns.

Authors:  Barbara Pergolizzi; Vitina Carriero; Giuliana Abbadessa; Claudia Penna; Paola Berchialla; Silvia De Francia; Enrico Bracco; Silvia Racca
Journal:  Mol Cell Biochem       Date:  2017-04-21       Impact factor: 3.396

Review 10.  Therapeutic significance of β-glucuronidase activity and its inhibitors: A review.

Authors:  Paul Awolade; Nosipho Cele; Nagaraju Kerru; Lalitha Gummidi; Ebenezer Oluwakemi; Parvesh Singh
Journal:  Eur J Med Chem       Date:  2019-12-04       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.